Moderna Inc
$ 47.44
-8.04%
05 Jun - close price
- Market Cap 18,823,541,000 USD
- Current Price $ 47.44
- High / Low $ 51.53 / 46.38
- Stock P/E N/A
- Book Value 18.66
- EPS -8.14
- Next Earning Report 2026-07-31
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.37 %
- 52 Week High 59.55
- 52 Week Low 22.28
About
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$43.20
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-01 | 2026-02-13 | 2025-11-06 | 2025-08-01 | 2025-05-01 | 2025-02-14 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -3.4 | -2.11 | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 |
| Estimated EPS | -2.11 | -2.6 | -2.16 | -2.97 | -3.11 | -2.7599 | -1.9 | -3.36 | -3.55 | -0.97 | -2.05 | -4.12 |
| Surprise | -1.29 | 0.49 | 1.65 | 0.84 | 0.59 | -0.1501 | 1.93 | 0.03 | 0.48 | 1.52 | -7.48 | 0.5 |
| Surprise Percentage | -61.1374% | 18.8462% | 76.3889% | 28.2828% | 18.9711% | -5.4386% | 101.5789% | 0.8929% | 13.5211% | 156.701% | -364.878% | 12.1359% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-31 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-06-06 13:37:11
Pfizer is entering the competitive obesity market with its experimental monthly weight-loss injection, berobenatide, aiming to challenge the dominance of Eli Lilly and Novo Nordisk. New Phase 2b clinical data presented at the American Diabetes Association conference showed significant weight reduction and continuous weight loss with a tolerable profile. The company is leveraging its acquisition of Metsera Inc. and extensive commercial network to prepare for global distribution, emphasizing the convenience of a once-a-month therapy and its potential to address comorbidities.
2026-06-06 11:30:03
Vestcor Inc reduced its stake in Merck & Co., Inc. by 8.1% in the fourth quarter, selling 22,707 shares and retaining 258,377 shares valued at $27.2 million. The article highlights positive investor sentiment towards Merck due to a $50 million settlement in Gardasil lawsuits and strong technical performance in its stock. Additionally, Merck reported solid quarterly earnings, beating estimates, and announced a quarterly dividend of $0.85 per share.
2026-06-06 11:08:08
Westfield Capital Management Co. LP initiated a new position in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, purchasing 53,552 shares valued at approximately $5.64 million. This investment highlights strong institutional interest in Merck, with other major holders like Vanguard and Geode also increasing their stakes. The article notes positive recent developments for Merck, including a significant Gardasil lawsuit settlement and strong performance in its oncology pipeline, particularly with Keytruda.
2026-06-05 20:39:40
Najat Khan, CEO of Recursion Pharmaceuticals (NASDAQ:RXRX), sold 23,588 shares of company stock for $84,459 on June 5, 2026, through a pre-arranged trading plan. Following this transaction, Ms. Khan still holds over 2.1 million shares. The sale occurred amidst recent company news, including mixed Q1 2026 earnings and a report highlighting AI's potential to significantly cut drug development costs.
2026-06-05 04:07:27
Jefferies upgraded Dominion Energy (D) from 'Hold' to 'Buy' and increased its price target to $76, representing a 14% upside. This upgrade follows the announcement of a $66.8 billion acquisition deal with NextEra Energy, which is expected to create the world's largest regulated electric utility. The analyst also cited Virginia House Bill 895, which expands renewable energy storage targets, as a factor supporting future EPS growth for Dominion Energy.
2026-06-04 19:26:06
Moderna (MRNA) stock rose 5.1% after presenting positive long-term data for its personalized mRNA-based cancer vaccine, developed with Merck, at the American Society of Clinical Oncology's annual meeting. The vaccine, combined with Keytruda, showed a 49% lower risk of cancer recurrence or death in high-risk melanoma patients and a 59% reduction in distant metastasis. This news, following previous positive clinical trial results for its flu and hantavirus vaccines, reinforces confidence in Moderna's mRNA platform beyond COVID-19.
